Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
- 浏览1
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



